{"id":1922,"date":"2021-12-02T12:04:27","date_gmt":"2021-12-02T11:04:27","guid":{"rendered":"http:\/\/invivo.partners\/portoflio_invivo\/integra-therapeutics\/"},"modified":"2021-12-02T12:42:16","modified_gmt":"2021-12-02T11:42:16","slug":"integra-therapeutics","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/","title":{"rendered":"Integra Therapeutics"},"content":{"rendered":"<p>Integra Therapeutics \u00e9s una empresa <em>spin-off<\/em> de la <strong>Universitat Pompeu Fabra (UPF)<\/strong>. La companyia es centra en el desenvolupament d\u2019una <strong>plataforma d\u2019edici\u00f3 gen\u00e8tica<\/strong> basada en la combinaci\u00f3 de <strong>sistemes CRISPR modificats<\/strong> amb <strong>integrases<\/strong> i <strong>transposases<\/strong> virals que permeten una <strong>integraci\u00f3<\/strong> estable i precisa de <strong>gens<\/strong> de <strong>qualsevol mida<\/strong>, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan <strong><em>in vivo<\/em><\/strong> com <strong><em>ex vivo<\/em><\/strong>.<\/p>\n<ul>\n<li>CEO i Cofundadora: Avencia S\u00e1nchez-Mej\u00edas<\/li>\n<li>CSO i Cofundador: Marc G\u00fcell Cargol<\/li>\n<li>Ubicaci\u00f3: Barcelona<\/li>\n<li>P\u00e0gina web: <a href=\"https:\/\/integra-tx.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">integra-tx.com<\/a><\/li>\n<\/ul>\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[507],"class_list":["post-1922","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-invivoventures"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Integra Therapeutics - Invivo Partners<\/title>\n<meta name=\"description\" content=\"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Integra Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-02T11:42:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/\",\"url\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/\",\"name\":\"Integra Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2021-12-02T11:04:27+00:00\",\"dateModified\":\"2021-12-02T11:42:16+00:00\",\"description\":\"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Integra Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Integra Therapeutics - Invivo Partners","description":"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/","og_locale":"ca_ES","og_type":"article","og_title":"Integra Therapeutics - Invivo Partners","og_description":"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.","og_url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/","og_site_name":"Invivo Partners","article_modified_time":"2021-12-02T11:42:16+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/","url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/","name":"Integra Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2021-12-02T11:04:27+00:00","dateModified":"2021-12-02T11:42:16+00:00","description":"Integra Therapeutics \u00e9s una empresa spin-off de la Universitat Pompeu Fabra (UPF). La companyia es centra en el desenvolupament d\u2019una plataforma d\u2019edici\u00f3 gen\u00e8tica basada en la combinaci\u00f3 de sistemes CRISPR modificats amb integrases i transposases virals que permeten una integraci\u00f3 estable i precisa de gens de qualsevol mida, per tal de tractar malalties gen\u00e8tiques i oncol\u00f2giques, tan in vivo com ex vivo.","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/integra-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Integra Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo\/1922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=1922"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tipo_portfolio?post=1922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}